Recently, anti-PD1/PDL1 together with anti-VEGFR blockage (atezolizumab+bevacizumab) has been introduced as first-line HCC therapy, and subsequently also anti-PDL1+anti-CTLA4 (durvalumab+tremelimumab).19 Here, PDCD1 is linked to hepatocellular carcinoma.